DRUG QUANTITY MANAGEMENT POLICY – PER DAYS

POLICY: Immunologicals – Fasenra Drug Quantity Management Policy – Per Days
- Fasenra® (benralizumab subcutaneous injection – AstraZeneca)

REVIEW DATE: 08/03/2022

OVERVIEW
Fasenra, an interleukin-5 receptor alpha (IL-5Rα)-directed cytolytic monoclonal antibody, is indicated for **severe asthma** as add-on maintenance treatment of patients ≥ 12 years of age who have an eosinophilic phenotype.[1] Limitations of Use: Fasenra is not indicated for the treatment of other eosinophilic conditions or for the relief of acute bronchospasm/status asthmaticus.

Dosing
Fasenra is administered as a subcutaneous injection.[1] The recommended dose is 30 mg administered once every 4 weeks for the first 3 doses, and then once every 8 weeks thereafter.

Availability
Fasenra is available as 30 mg/mL single-dose, prefilled pens and syringes.[1] Each carton contains one pen or syringe.

POLICY STATEMENT
This Drug Quantity Management program has been developed to promote the safe, effective, and economic use of Fasenra. If the Drug Quantity Management rule is not met for the requested medication at the point of service, coverage will be determined by the Criteria below. All approvals will be provided for the duration noted below.

Automation: None.

Drug Quantity Limits

Product	Strength and Form	Retail Maximum Quantity per 56 days	Home Delivery Maximum Quantity per 56 days
Fasenra® (benralizumab subcutaneous injection)	30 mg/mL prefilled syringes	1 syringe	1 syringe
	30 mg/ mL prefilled pens	1 pen	1 syringe

CRITERIA
Fasenra 30 mg/mL prefilled pens and prefilled syringes

1. If the patient is initiating therapy at induction dosing for asthma, as verified by the absence of claims for Fasenra in the past 130 days, approve a one-time override for three prefilled pens or three prefilled syringes for an 84-day supply at retail and at home delivery.

REFERENCES

1. Fasenra® subcutaneous injection [prescribing information]. Wilmington, DE: AstraZeneca; October 2019.